EV-302 Results and How They Compare to the JAVELIN Paradigm

A roundtable discussion, moderated by Peter O’Donnell, MD, discussed the advanced urothelial treatment landscape, as well as recent trial data from ESMO 2023. Dr. O’Donnell was joined by Terence Friedlander, MD; Matthew Galsky, MD; and Jonathan Rosenberg, MD. In the next segment of the roundtable series, the panel discussed how the EV-302 data compare to the previous JAVELIN paradigm in patients with bladder cancer.